Pipeline
ABL001
HomePipelineABL001
-
- Pipeline
- ABL001
-
- Program Target
- VEGF x DLL4
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- Clinical Development
(Phase 1a/1b)
- Summary
- Better anti-cancer efficacy of ABL001 at in vitro/in vivo studies are confirmed with cancer patients in clinical trial (phase 1a/1b).
ABL001 can be developed as the next generation of anti-angiogenic therapy.
MOA of ABL001
Dual blockade of VEGF & DLL4 overcomes VEGF resistance
POC of ABL001 in Preclinical Study
Better efficacy compared to Avastin or anti-DLL4 monotherapy
Clinical Response of ABL001
3 Patients showed confirmed partial response (PR) in phase 1a/1b study
Publications
| Pipeline | Jernal | Date | Title | Link | |
|---|---|---|---|---|---|
| ABL001 | mAbs | 2016 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |  |
 |
| BMB Reports | 2020 | Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer | |
|
|
| Int J Mol Sci | 2020 | ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models | |
|
Posters
| Pipeline | Name | Title | |
|---|---|---|---|
| ABL001 | PEGS 2017 | Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 | |
| ASCO 2019 | Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer | |
|
| PEPTALK 2020 | Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors | |